RASGRP1 and acute lymphoblastic leukemia: Oncogenic Ras signals are observed in ~65% of T-ALL patients [5, 6], either via an oncogenic RAS mutation, inactivation of the NF1 tumor suppressor, or overexpression of the activator Ras guanine nucleotide releasing protein 1 (RasGRP1) [7, 8].